博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300404 博济医药

已收盘 01-13 15:00:00

{"stockData":{"symbol":"300404","market":"SZ","secType":"STK","nameCN":"博济医药","latestPrice":12.92,"timestamp":1768287825000,"preClose":10.77,"halted":0,"volume":62712325,"delay":0,"changeRate":0.1996,"floatShares":281000000,"shares":386000000,"eps":0.0193,"marketStatus":"已收盘","change":2.15,"latestTime":"01-13 15:00:00","open":11.01,"high":12.92,"low":11.01,"amount":776000000,"amplitude":0.1773,"askPrice":0,"askSize":0,"bidPrice":12.92,"bidSize":89458,"shortable":0,"etf":0,"ttmEps":0.0193,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":10.77,"symbolType":"stock","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":11.85,"lowLimit":9.69,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":385732498,"isCdr":false,"pbRate":4.07,"roa":"--","peRate":669.430052,"roe":"2.21%","epsLYR":0.0753,"committee":0,"marketValue":4984000000,"turnoverRate":0.2233,"status":0,"floatMarketCap":3628000000},"requestUrl":"/m/hq/s/300404","defaultTab":"news","newsList":[{"id":"2603573633","title":"异动快报：博济医药（300404）1月13日9点42分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2603573633","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603573633?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:45","pubTimestamp":1768268747,"startTime":"0","endTime":"0","summary":"证券之星1月13日盘中消息，9点42分博济医药触及涨停板。其所属行业医疗服务目前上涨。领涨股为泓博医药。该股为减肥药，AI医疗，CAR-T疗法概念热股，当日减肥药概念上涨2.14%，AI医疗概念上涨1.93%，CAR-T疗法概念上涨1.51%。1月12日的资金流向数据方面，主力资金净流出1468.01万元，占总成交额5.89%，游资资金净流入1085.22万元，占总成交额4.36%，散户资金净流入382.79万元，占总成交额1.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300009291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2602577725","title":"股市必读：博济医药（300404）1月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602577725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602577725?lang=zh_cn&edition=full","pubTime":"2026-01-12 02:53","pubTimestamp":1768157588,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，博济医药报收于10.55元，上涨1.05%，换手率6.65%，成交量18.66万手，成交额1.95亿元。董秘最新回复投资者： 希望公司能加倍努力提高营收增速，并将净利提升到5000万以上董秘： 您好，公司各业务板块技术人员均在全力推进项目进度，全力以赴推动公司业务持续增长。当日关注点来自“交易信息汇总”：1月9日主力资金净流出474.82万元，游资资金净流出837.65万元，散户资金净流入1312.47万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2602253003","title":"博济医药：公司在CAR-T细胞疗法等领域提供临床研究服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2602253003","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602253003?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:36","pubTimestamp":1767947770,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药01月09日在投资者关系平台上答复投资者关心的问题。博济医药回复：您好，1、公司在相关领域均积累了丰富的经验，目前也有为客户提供如CAR-T细胞疗法治疗肿瘤等以及干细胞治疗肝病、肠炎等临床研究服务；脑科类医疗器械方面有为客户提供无创脑神经刺激器治疗抑郁症等临床研究服务，但具体项目因涉及客户商业机密，不便透露，敬请谅解。公司严格按照项目进度确认收入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900025075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2601182531","title":"博济医药：司美格鲁肽注射液项目进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2601182531","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601182531?lang=zh_cn&edition=full","pubTime":"2026-01-07 11:36","pubTimestamp":1767756975,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药(300404)01月06日在投资者关系平台上答复投资者关心的问题。投资者提问：诺泰生物委托贵公司研发的司美格鲁肽注射液研发进展情况。何时能够提交上市申报？博济医药回复：您好，公司为该项目提供三期临床研究服务，涉及降糖及减重两个适应症，目前项目进展顺利，具体进度因涉及客户商业机密，不便透露，敬请谅解。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700013970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2601877825","title":"博济医药：九泰药械提供脑神经医疗器械临床研究服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2601877825","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601877825?lang=zh_cn&edition=full","pubTime":"2026-01-07 11:34","pubTimestamp":1767756843,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药01月06日在投资者关系平台上答复投资者关心的问题。有媒体报道贵公司子公司九泰药械目前有为诸如植入式脑深部刺激系统、磁刺激调控治疗抑郁症等脑神经科学方面的医疗器械提供临床研究服务，消息是否属实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700013784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1222","09996","BK0216","BK1100","300404","09997","BK1574","159883","BK1583"],"gpt_icon":0},{"id":"2593435276","title":"博济医药（300404）披露控股股东部分股份解除质押，12月22日股价下跌0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593435276","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593435276?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:54","pubTimestamp":1766415281,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，博济医药报收于9.54元，较前一交易日下跌0.52%，最新总市值为36.8亿元。公司近日发布公告称，控股股东王廷春先生近日将其持有的19,000,000股公司股份在国泰海通证券股份有限公司办理了股份解除质押手续，占其所持股份比例的16.86%，占公司总股本的4.93%。本次解除质押后，王廷春及其一致行动人所持公司股份无任何质押情况。本次解除质押不会对公司经营、公司治理产生影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200035687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2590516326","title":"博济医药：12月10日高管王廷春减持股份合计134万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516326","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590516326?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:02","pubTimestamp":1765458156,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月11日市场公开信息、上市公司公告及交易所披露数据整理，博济医药（300404）最新董监高及相关人员股份变动情况：2025年12月10日公司董事,高管王廷春共减持公司股份134.0万股，占公司总股本为0.3474%。变动期间公司股价下跌0.62%，12月10日当日收盘报9.56元。博济医药近半年内的董监高及核心技术人员增减持详情如下：博济医药的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100038707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2590158809","title":"12月10日博济医药现1183.22万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2590158809","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590158809?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:43","pubTimestamp":1765359800,"startTime":"0","endTime":"0","summary":"证券之星消息，12月10日博济医药发生大宗交易，交易数据如下：近三个月该股共发生11笔大宗交易，合计成交7.66万手，折价成交11笔。该股在过去半年内已有共计23.0万股限售解禁股上市，占公司总股本的0.06%。截至2025年12月10日收盘，博济医药(300404)报收于9.56元，下跌0.62%，换手率1.71%，成交量4.79万手，成交额4572.28万元。该股近半年内有股东持股变动，合计净减持116.1万股，股东增减持明细如下表：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000028219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2590314523","title":"12月9日博济医药现1526.26万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2590314523","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590314523?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:42","pubTimestamp":1765273347,"startTime":"0","endTime":"0","summary":"证券之星消息，12月9日博济医药发生大宗交易，交易数据如下：近三个月该股共发生8笔大宗交易，合计成交6.32万手，折价成交8笔。该股在过去半年内已有共计23.0万股限售解禁股上市，占公司总股本的0.06%。截至2025年12月9日收盘，博济医药(300404)报收于9.62元，下跌0.72%，换手率1.45%，成交量4.08万手，成交额3949.19万元。该股近半年内有股东持股变动，合计净减持116.1万股，股东增减持明细如下表：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900027355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2590157343","title":"博济医药：在研项目众多并以创新药为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2590157343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590157343?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:12","pubTimestamp":1765267934,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药(300404)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：公司重视创新药的研发吗？博济医药回复：您好，近几年公司不断引入优秀人才，着力提升公司创新药研发的能力。目前公司在研服务的项目众多并以创新药为主，涵盖化药、生物药、中药药物类别。此外，公司也有处于不同阶段的创新药自研项目，该类项目由公司自主立项，拥有自主知识产权。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900020841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","06978","159992","BK0216","300404"],"gpt_icon":0},{"id":"2588884762","title":"博济医药：12月3日高管王廷春减持股份合计240.91万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884762","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588884762?lang=zh_cn&edition=full","pubTime":"2025-12-04 21:02","pubTimestamp":1764853332,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月4日市场公开信息、上市公司公告及交易所披露数据整理，博济医药（300404）最新董监高及相关人员股份变动情况：2025年12月3日公司董事,高管王廷春共减持公司股份240.91万股，占公司总股本为0.6246%。变动期间公司股价下跌1.81%，12月3日当日收盘报9.74元。博济医药近半年内的董监高及核心技术人员增减持详情如下：博济医药的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400037359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2588537460","title":"博济医药：12月1日高管王廷春减持股份合计48万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588537460","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588537460?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:03","pubTimestamp":1764680599,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月2日市场公开信息、上市公司公告及交易所披露数据整理，博济医药（300404）最新董监高及相关人员股份变动情况：2025年12月1日公司董事,高管王廷春共减持公司股份48.0万股，占公司总股本为0.1244%。变动期间公司股价下跌0.7%，12月1日当日收盘报9.94元。博济医药近半年内的董监高及核心技术人员增减持详情如下：博济医药的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200037340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2588725881","title":"12月1日博济医药现690.4万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2588725881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588725881?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:42","pubTimestamp":1764582143,"startTime":"0","endTime":"0","summary":"证券之星消息，12月1日博济医药发生大宗交易，交易数据如下：近三个月该股共发生2笔大宗交易，合计成交7300.0手，折价成交2笔。该股在过去半年内已有共计23.0万股限售解禁股上市，占公司总股本的0.06%。截至2025年12月1日收盘，博济医药(300404)报收于9.94元，下跌0.7%，换手率2.97%，成交量8.33万手，成交额8308.38万元。该股近半年内有股东持股变动，合计净减持116.1万股，股东增减持明细如下表：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100022414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2586473871","title":"博济医药：为客户提供流感治疗临床研究服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2586473871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586473871?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:52","pubTimestamp":1764075175,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药(300404)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：现在流感盛行，请问贵公司有利用AI制药研发生产甲流或者其他流感新药吗？谢谢！博济医药回复：您好，目前公司暂未自主研发相关药物，但有为客户提供多个针对不同受试人群的治疗甲型流感、普通流感及其他急性上呼吸道感染的临床前、临床研究服务，并积极借助AI技术提高效率和质量。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500036314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2584955963","title":"博济医药（300404）披露日常经营合同进展公告，11月18日股价下跌1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584955963?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:31","pubTimestamp":1763476286,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，博济医药报收于10.45元，较前一交易日下跌1.51%，最新总市值为40.31亿元。该股当日开盘10.53元，最高10.7元，最低10.38元，成交额达1.34亿元，换手率为4.52%。本次补充协议无需董事会审议，不构成关联交易和重大资产重组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800040065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2582670583","title":"博济医药（300404）披露子公司获得药物临床试验批准通知书，11月11日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582670583","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582670583?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:40","pubTimestamp":1762872034,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，博济医药报收于10.18元，较前一交易日上涨0.39%，最新总市值为39.27亿元。该股当日开盘10.14元，最高10.22元，最低10.05元，成交额达1.02亿元，换手率为3.58%。公司近日发布公告称，其全资子公司广州博济新药临床研究中心有限公司申报的“卿芷软膏”已获得国家药品监督管理局签发的《药物临床试验批准通知书》，同意该药品开展用于膝骨关节炎的临床试验。公告显示，卿芷软膏为中药1.1类创新药，适应症为膝骨关节炎风寒湿痹证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2582555753","title":"博济医药(300404.SZ)子公司卿芷软膏获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582555753","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582555753?lang=zh_cn&edition=full","pubTime":"2025-11-11 15:47","pubTimestamp":1762847233,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博济医药(300404.SZ)发布公告，近日，公司全资子公司广州博济新药临床研究中心有限公司申报的“卿芷软膏”获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。“卿芷软膏”为多味饮片在中医药理论指导下组方而成的制剂，属于未在境内外上市的中药新处方制剂，为1.1类中药创新药。本药品用于膝骨关节炎风寒湿痹证，主治祛风胜湿，散寒通络，行气止痛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","300404"],"gpt_icon":0},{"id":"2579156277","title":"博济医药（300404）2025年三季报简析：增收不增利，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2579156277","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579156277?lang=zh_cn&edition=full","pubTime":"2025-10-30 08:06","pubTimestamp":1761782765,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博济医药发布2025年三季报。截至本报告期末，公司营业总收入5.84亿元，同比上升5.07%，归母净利润2191.39万元，同比下降49.36%。本报告期博济医药公司应收账款体量较大，当期应收账款占最新年报归母净利润比达679.65%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202510/30/20251030396683.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202510/30/20251030396683.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251030/31748836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300404","BK0216"],"gpt_icon":0},{"id":"2578930471","title":"图解博济医药三季报：第三季度单季净利润同比下降51.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578930471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578930471?lang=zh_cn&edition=full","pubTime":"2025-10-28 18:54","pubTimestamp":1761648847,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药2025年三季报显示，公司主营收入5.84亿元，同比上升5.07%；归母净利润2191.39万元，同比下降49.36%；扣非净利润1498.12万元，同比下降57.06%；其中2025年第三季度，公司单季度主营收入2.23亿元，同比上升3.78%；单季度归母净利润634.4万元，同比下降51.73%；单季度扣非净利润299.29万元，同比下降67.57%；负债率33.62%，投资收益42.26万元，财务费用98.03万元，毛利率28.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800035238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404"],"gpt_icon":0},{"id":"2578660658","title":"博济医药：持续发展临床前药学研究和药物评价业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2578660658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578660658?lang=zh_cn&edition=full","pubTime":"2025-10-28 09:01","pubTimestamp":1761613272,"startTime":"0","endTime":"0","summary":"投资者提问：建议公司增加药物研发投入，增强公司在临床前cro服务商中的地位与市场占有率，早日跻身top10。公司是一家专业的CRO服务提供商，以临床试验服务为主，近几年公司营收也持续增长，未来在保持临床试验服务优势的前提下，持续发展临床前药学研究和药物评价业务并持续加强自主创新能力，稳步开发自主研发品种，着手推进主营业务链条的医药合同定制研发生产服务，充分发挥“一站式”全流程服务的优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800009832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768297022584,"stockEarnings":[{"period":"1week","weight":0.0569},{"period":"1month","weight":0.1397},{"period":"3month","weight":0.1289},{"period":"6month","weight":0.0548},{"period":"1year","weight":0.3648},{"period":"ytd","weight":0.1543}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":0.0709},{"period":"3month","weight":0.0776},{"period":"6month","weight":0.1888},{"period":"1year","weight":0.3146},{"period":"ytd","weight":0.0495}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"博济医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"29555人(较上一季度增加18.91%)","perCapita":"9500股","listingDate":"2015-04-24","address":"广东省广州市黄埔区科学城南翔一路62号(二、三、四、五)栋","registeredCapital":"38573万元","survey":"　　博济医药科技股份有限公司的主营业务是为国内外制药企业及其他研究机构就新药品、医疗器械的研发与生产提供全流程“一站式”CRO服务。公司的主要产品是临床研究服务、临床前研究服务、临床前自主研发、其他咨询服务。作为国内领先的CRO公司，公司在报告期内荣膺“2024中国医药CRO企业20强（排名第8）”“2024年度中国医药研发50强”“中国生命科学服务企业百强”卓越成就奖等荣誉称号。","listedPrice":12.87},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博济医药(300404)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博济医药,300404,博济医药股票,博济医药股票老虎,博济医药股票老虎国际,博济医药行情,博济医药股票行情,博济医药股价,博济医药股市,博济医药股票价格,博济医药股票交易,博济医药股票购买,博济医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博济医药(300404)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}